Talaris Therapeutics, Inc. Banner Image

Talaris Therapeutics, Inc.

  • Ticker TALS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Talaris Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Louisville, Kentucky
Tourmaline Bio is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Tourmaline’s lead program, TOUR006, is an anti-IL-6 antibody which exhibits best-in-class properties including high binding affinity to IL-6 and a naturally long half-life. To date, TOUR006More has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline plans to develop TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its lead and secondary indications, respectively, with additional indications under consideration.
Talaris Therapeutics, Inc.

Most Recent Annual Report

Talaris Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Talaris Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!